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Summary A tumour model system is reported that for many purposes may be an alternative to xenografted
nude mice. The model allows immunotargeting of human tumour cells in immunocompetent animals. The
target cells are contained in i.p. diffusion chambers (DC) with micropore membrane walls that are permeable
to molecules, including the cell specific monoclonal antibodies (MoAb), but impermeable to cells. Thus, the
tumour cells are protected from the host immunocompetent cells. In the work here presented the model was
tested in immunocompetent mice and pigs, with tumour cells and antibody preparations that had demon-
strated specific targeting in the nude mouse xenograft model. Hence, the DC were filled with cells from the
human cell lines Hep-2 (expressing placental alkaline phosphatase, PLALP), or OHS (a sarcoma cell line), and
the MoAb preparations injected i.v. were a 125I-labelled Fab fragment of the PLALP specific antibody H7, or a
'251-labelled F(ab')2 fragment of the sarcoma specific antibody TP-1. Specific targeting of the human tumour
cells was demonstrated in both mice and pigs. The target:blood ratios were comparable in the two species,
reaching a maximum of about 15 after 24 h with the Fab preparation, and a ratio of 25 after 72 h with the
F(ab')2. The target uptake relative to injected dose was lower in pigs than in mice, but the difference between
the two species was smaller than expected, presumably due to a slower antibody clearance in the pigs than in
the mice. An artificial cell targeting system like this has several advantages in the search for solutions to many
of the fundamental problems experienced in immunotargeting. Firstly, parallel binding experiments can be
carried out in vitro with the same target. Because in vitro results are only influenced by the diffusion into the
DC and the immunological binding characteristics of the antibodies, targeting differences between antibody
preparations due to these factors can then be distinguished from differences due to pharmacokinetical
properties. Secondly, the animals can be implanted with any type and number of target cells, or with antigen
negative control cells. Thirdly, and perhaps most important, the system opens a possibility for evaluation of
the murine MoAb in xenogeneic species, and this may predict the clinical targeting potential better than
experiments on mice.
Radioimmunotargeting is based on the high specificity of
antigen-antibody reactions. The method can be used for diag-
nostic as well as therapeutic purposes, depending on the dose
and the physical properties of the radioactive label. Tumour
visualisation is often hampered by insufficient tumour uptake
and a too high antibody level in blood and non-tumour
tissues. When used for immunotherapy, a such unfavourable
antibody distribution would given an insufficient radioactiv-
ity dose in the tumour, and a detrimental dose to normal
tissues.
Preclinical in vivo procedures with experimental animals,
most often xenografted nude mice, are currently performed
to restrict patient trials to the most promising anti-tumour
antibodies. However, the nude mouse xenograft system has
some important limitations. Firstly, the predictive value of
the nude mouse model is reduced because most MoAb are
produced in mice, so that the model does not test a xeno-
geneic antibody transfer, as occurs when murine MoAb are
injected into patients. A large number of MoAb predict an
excellent targeting potential when testing in the nude mouse
model, whereas disappointingly few antibodies seem to give
satisfactory tumour targeting in patients. Secondly, the
growth rate of xenografted tumours varies between individ-
ual animals, giving heterogeneous tumour sizes that increase
the variation in the experimental results. Thirdly, athymic
nude mice are expensive, and require expensive housing con-
ditions to be protected from infections.
Recently, a novel method for preclinical in vivo evaluation
of anti-tumour MoAb was published from our institution.
The method is based on diffusion chambers implanted in the
peritoneal cavity of conventional laboratory animals, and
was successfully used for targeting of antigen-coated polymer
particles (Fjeld et al., 1988). In the report here presented,
human tumour cells rather than antigen-coated polymer par-
ticles were used. Importantly, with this DC tumour model it
is possible to carry out targeting studies with the same MoAb
preparations and tumour cell lines in any animal species large
enough to carry the DC. Thus, to be able to compare
xenogeneic and allogeneic transfer of the anti-tumour anti-
bodies, we have chosen both domestic pigs and conventional
laboratory mice as experimental animals. Antibody fragments
do most often show improved tumour imaging characteristics
compared with intact antibodies (Buchegger et al., 1983;
Andrew et al., 1988). Two fragmented MoAb will be tested
in the DC model in this paper.
Materials and methods
Animals
Mice The mice were randomly bred females (NMRI/Bom),
8-12 weeks of age and 20-25 g in weight.
Pigs Female domestic pigs were used. These animals were 4
months of age and 20 kg in weight.
Difusion chambers (DC)
Preparation of DC We used the same type of chambers as
described in our previous work on DC with antigen-coated
polymer particles (Fjeld et al., 1988). The DC consisted of
two micropore membranes (Millipore GSWP, mean pore
diameter 0.22jAm) heat sealed to both sides of a 2 mm thick
acrylic plastic ring, outer diameter 13 mm (Benestad & Reik-
vam, 1975). The DC were filled with 160;&l suspension of one
of the two tumour cell lines (see below) in Dulbecco's Modi-
fied Eagle Medium (Gibco Limited, UK) with 10% FCS, or
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with the cell medium only as a cell free control. Each DC
contained 160pl cell suspension, and the number of cells in
mice was 2 x 105 cells per DC, and from I04 to 106 cells per
DC in pigs. When viability was tested with the trypan blue
dye exclusion test, the implanted cell suspensions contained
about 5% dead cells, increasing to about 10% after 24 h, and
20-40% after 72 h. There was no significant change in the
total number of cells (dead + viable) during the observation
period. Each DC was marked with waterproofink, indicating
the chamber content.
DC implantation in mice Two DC were i.p. implanted in
each mouse through a midline ventral incision; one target
DC and one control. The operation was carried out under
ether anaesthesia the day before antibody injection. The
wounds were closed with metal clips, and the mice were kept
in conventional cages with free access to food and water.
DC implantation in pigs The animals were preoperatively
sedated with azaperone, followed by anaesthesia with meto-
midate chloride i.v. during the operation. The pigs received
30 DC each, through a small midline laparothomy. These
chambers contained different dilutions of cells, as described
above, with triplicates for each dilution. The wounds were
suturated, and the animals were kept in conventional cages
with free access to food and water.
Tumour cell lines
Two cell lines of human origin were used. The cervix cancer
cell line HeLa, strain Hep-2, expresses placental alkaline
phosphatase (PLALP), and these cells bind the monoclonal
antibody (MoAb) H7. The second cell line was the osterosar-
coma line OHS, which has been established at the Norwegian
Radium Hospital (Fodstad et al., 1986), and the sarcoma
specific MoAb TP-1 binds to OHS epitopes.
Antibodies
The fragmented antibody preparations used The monoclonal
antibody H7 (IgG2a) recognises the three common allelic
variants of PLALP (Millan & Stigbrand, 1983). The mono-
clonal antibody TP-1 (IgG2a) (Bruland et al., 1986) is specific
for an epitope on a sarcoma associated antigen (Bruland et
al., 1988). The immunoglobulin fractions were separated
from ascites with affinity chromatography on protein-A
Sepharose columns (Pharmacia, Sweden), and purity was
controlled with Fast Protein Liquid Chromatography (FPLC,
Pharmacia, Sweden), or polyacrylamide gel electrophoresis,
as earlier described for both H7 (Fjeld et al., 1988), and TP-1
(Bruland et al., 1987).
The two MoAb were enzymatically digested before they
were used in vivo. H7 was enzymatically fragmented to Fab
with papain (Goding, 1983; Fjeld et al., 1988), and TP-1 to
F(ab')2 with pepsin (Parham, 1983; Bruland et al., 1987).
Iodination of antibodies The fragmented antibodies were
'251-labelled with Iodogen (Pierce, USA) as oxidant (Fracker
& Speck, 1978). We followed a standard procedure estab-
lished in our laboratory (Paus et al., 1982).
Quality control of the iodinated antibodies Binding assays
were carried out by mixing 50 ILI of '25I-labelled MoAb dilu-
tion with 50 ,sl of serial dilutions of Hep-2 or OHS cells,
respectively. The reactants had been diluted in PBS with
0.1% BSA. The reaction mixtures were incubated at 20°C for
at least 3 h with continuous shaking. Free, labelled MoAb
were then separated from cell-bond MoAb by washing twice
with 1 ml of the dilution buffer. The cells were collected by
centrifugation, and the bound radioactivity was counted in a
gamma-counter. The immunoreactive fraction (F) of the
labelled antibody preparation, the antibody association con-
stant (Ka) and the number of binding sites (S) per cell were
calculated from the experimental data on the assumption that
the reactions obey the first order law of mass action. A
computerised iteration technique was utilised to achieve the
parameter values that give optimal fitness of the experimental
values with the mass action law (Fjeld & Skretting, manu-
script in preparation). Shortly, the assumptions made by us
for the reaction between antigen and antibody were the same
as the assumptions for most of the plot methods utilised, for
example the Scatchard plot (Scatchard, 1949), i.e. a reversible
bimolecular reaction following second order kinetics. The
difference is that a computational fitting procedure was
utilised in exchange for a graphical curve fitting by the eye. The procedure was limited to experimental values giving between 30 and 100% binding of the immunoreactive frac-
tion of the '25I-MoAbs.
Intravenous injection in mice The next day after the DC
implantation, the mice were injected i.v. (tail vein) with
6pmol '25l-labelled antibodies per mouse (equivalent to
0.3 fg H7-Fab; or 0.6jig TP-l-F(ab')2) diluted in 0.9% NaCI
with 0.1% normal mouse serum (200 lI per mouse).
Intravenous injection in pigs 1251I-labelled MoAb was injected
i.v. (ear vein) immediately after the DC implantation, while
the pigs were still in deep anaesthesia. Each pig received
1,200pmol antibody (equivalent to 55;tg H7-Fab; or 120 ltg TP-l-F(ab')2) in a volume of 5 ml per animal.
DC and tissue harvest
Mice Blood, tissue specimens, and the DC were collected
from animals killed by ether overdosage at various time
intervals during the next 3 days after the injection. The
radioactivity in the whole DC with its tumour cell content,
and in blood samples and tissue specimens were counted in a
gamma counter.
Pigs The pigs remained anaesthetised during the first 2-3 h
period after the DC implantation, because multiple blood
samples were collected during this period. The blood was
collected from the ear vein, or from veins in the thoracic
outlet. They were killed by an overdose of phenobarbitone
after a period of 1-3 days, depending on which antibody
preparation that had been injected. Like in the mouse experi-
ments, the distribution and tumour cell targeting of the
labelled antibodies were studied by recording in a gamma-
counter the radioactivity in blood, various tissues, and all the
different DC in the peritoneal cavity.
Results
Binding characteristics ofthe antibodies and the tumour cells
The two '25I-labelled antibody preparations chosen for the
targeting experiments were first tested in vitro against cell
suspensions from the cell lines Hep-2 and OHS. The Fab
fragment of the MoAb H7 (H7-Fab) did bind to Hep-2, and
the F(ab')2 fragment of TP-1 (TP-1-F(ab')2) to OHS (Figure
1). The non-specific binding of H7-Fab to OHS and of
TP-l-F(ab')2 to Hep-2 was only about 1% of total radio-
activity (not shown in Figure 1).
The binding parameters of the iodinated preparations were
then estimated, using a mathematical model derived from the
first order law of mass action. A computerised non-linear
least-squares fit to the experimental data yielded the binding
parameters (Fjeld & Skretting, manuscript in preparation).
The estimated association constant of H7-Fab was closed to
ten times the association constant of the TP-1-F(ab')2, where-
as the immunoreactive fraction as well as the number of
binding sites per target cell was higher for the TP-l-F(ab')2
than for H7-Fab (Table I).
Immunotargeting oftumour cells in immunocompetent mice
The two antibody preparations had previously been used in
the nude mouse xenograft model system (Bruland et al.,RADIOIMMUNOTARGETING OF TUMOUR CELLS 575
100
80-
-
> 0 * 60
CU>-
0 =
tU- 40-
O a) o
Cn
20 -
0
0-
9-"
2 4 6
Number of cells x 10-5
8
Figure 1 In vitro binding of '251I-labelled H7-Fab to Hep-2 cell
suspensions (O---0), and of 251I-labelled TP-1-F(ab')2 to OHS
(0 *). A constant amount of251I-labelled antibodyin 50Il& was
added to 50ItI aliquots of serial dilutions of target cells. After
incubation at 20°C for at least 3 h, followed by two washes, the
amount of cell bound radioactivity was counted. The results have
been corrected for non-specific binding to the other cell line, and
the antibodies were highly selective for their target cells, with
only about 1% non-specific binding. Medians for triplicates.
Table I Binding parameters for the '25I-MoAb preparations
Immunoreactive Association No. sites
fraction constant per cell
(%) (Imol-') ( x 10-5)
TP-l-F(ab')2 83 7.4 x 108 6.4
vs OHS cells
H7-Fab 57 6.0 x 109 4.0
vs Hep-2 cells
The binding assay and the calculation ofthe parameters was carried
out as described in Materials and methods. The experimental results
used in the calculations are presented in Figure 1.
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Figure 2 Blood concentrations of '251-labelled H7-Fab
(O- --0) and TP-I-F(ab')2 (@ 0) injected i.v. on mice.
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1987; Fjeld, unpublished results). Moreover, the H7 prepara-
tion had also shown specific targeting of antigen coated
polymer particles in normal mice (Fjeld et al., 1988).
The in vivo uptake of a radiolabelled antibody in its
specific target depends, among several other factors, on the
antibody concentration in the blood. Thus, the DC targeting
experiments were preceded by blood clearance studies with
the anti-tumour antibodies in immunocompetent mice
(Figure 2). The Fab fragment of H7 was, as expected, more
rapidly cleared from the blood circulation than the larger
F(ab')2 fragment of TP-1. The next day after the injection the
blood level of both antibodies was low, but significantly
different, with a value of 0.1% injected dose for H7-Fab and
5% for TP-I-F(ab')2. It was necessary to wait for 2 more
days before the level of the TP-1 preparation had decreased
to the low level reached by the H7 preparation after only 1
day.
Based on these blood clearance studies, it was decided to
compare the biodistribution and tumour cell targeting 24 and
72 h after the antibody injection. Each mouse carried two
DC, one filled with 2 x 105 OHS cells, and the second with
the same amount of Hep-2 cells. The results demonstrated
that the anti-sarcoma antibody TP-I-F(ab')2 was specifically
bound to DC filled with cells from the sarcoma cell line
OHS, whereas the anti-PLALP antibody H7-Fab was specifi-
cally bound to DC containing the PLALP expressing Hep-2
cells (Figure 3). Moreover, the DC:blood ratio with the TP-1
preparation was significantly increased in the period from 1
to 3 days. In contrast, the DC:blood ratio with the H7
preparation decreased from day 1 to day 3. The explanation
to the latter seemed to be that there had been a net release of
radioactivity from the target in the period between day 1 and
day 3 (Table II), whereas the blood level remained almost
unchanged (Figure 2). The explanation to the increased
target:blood ratio with TP-1-F(ab')2 seemed to be no change,
or a minor increase, in the net radioactivity uptake in the DC
Figure 3 Biodistribution and human tumour cell immunotarget-
ing in mice 24 h and 72 h after antibody injection i.v. Each mouse
carried two DC, one filled with human tumour cell suspension,
and the other with control cells. The DC contained 2 x 101 cells
in a volume of 160IlI cell medium, and the radioactivity in tissue
specimens and the DC were therefore related to the radioactivity
in 160 slA blood. Medians and ranges for groups of three DC are
shown. There were only minor differences between the tissue
results, and these ranges were therefore not drawn.
Table II Percentage of administered dose of '251-MoAb specifically
bound to human target cells in intraperitoneal DC in mice
Time after i.v. Ratio
injection (h) TP-1-F(ab')2 H7-Fab TP-1-F(ab')2:H7-Fab
24 1.8% 0.21% 8.6
(1.4-1.9) (0.20-0.35)
72 1.8% 0.13% 13.8
(1.6-2.4) (0.09-0.16)
Each DC contained 2 x 10 target orcontrol cells. Each mouse, with
one target and one control DC, was injected i.v. with 6 pmol antibody.
The results were corrected for the non-specific binding to control DC.
Medians and ranges for groups of three DC.
between 1 and 3 days (Table II), whereas the blood level had
decreased during the same period (Figure 2).
The uptake in DC filled with the cell medium only was not
significantly different from the DC with the control cells
(results not shown). Thus, the radioactivity in the control DC
did mostly represent non-specific binding to the chamber
components, and unbound antibodies in the fluid within the
DC.
In vitro DC studiesparallel to the mouse experiments
With the artificial tumour system here presented, a compari-
son between in vitro and in vivo uptake could be performed.
At
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Table In In vitro targeting of DC with human tumour cells
Incubation Ratio
time (h) TP-1-F(ab')2 H7-Fab TP-1-F(ab')2:H7-Fab
24 10.9% 7.8% 1.4
(9.2-11.4) (7.2-7.9)
72 12.9% 6.9% 1.9
(10.8-13.7) (3.9-7.8)
Testtubeswith 10 mlcellmedium and 0.3 pmol '25l-labelled antibody
added were used. Each tube contained three DC with 2 x iOs target
cells, and three DC with the same number of control cells. The tubes
were rotated end over end at 37°C. Percentage ofadded dose bound to
thetarget DCisshown, corrected forthenon-specificbinding tocontrol
DC. Medians and ranges for three DC.
It is then possible during evaluation of the immunotargeting
capacity of an antibody, to distinguish between pharmaco-
kinetical and immunological factors. In vitro, the specific DC
binding was somewhat higher with TP-1 than with H7; after
24 h there was a 1.4 times higher TP-1 uptake, increasing to
1.9 times at 72 h (Table III). This minor difference between
the two antibodies in vitro was in contrast to the results in
the peritoneal cavity of mice, where a definitely larger differ-
ence was recorded; after 24 h there was a 8.6 times higher in
vivo uptake of the TP-1 antibody than of H7, increasing to a
ratio of 13.8 after 72 h (Table II). Thus, when comparing the
targeting potential of these two antibodies, it seems that most
of the difference between their tumour cell uptake was caused
by pharmacokinetical differences between Fab and F(ab')2,
and only a minor part was due to different immunological
binding characteristics.
Immunotargeting oftumour cells in domestic pigs
Like in the mouse experiments, the blood clearance of the
two antibody preparations was recorded in the pigs before
the targeting experiments were carried out (Figure 4). Guided
by these clearance curves, a 24 h period between MoAb
injection and DC harvest was chosen for Fab, and a 72 h
period for F(ab')2, e.g. the same time intervals that had given
optimal targeting in the mice. The clearance rate of both
antibodies was slower in the pigs than in mice. A higher
blood level of antibodies in the pigs should enhance the
tumour uptake in this species. With the intention to decrease
the effect of this difference in clearance rate on the concentra-
tion of antibody available for the tumour cells during the
study, the antibody doses given to the pigs were only in-
creased 200 times relative to the doses injected on the mice,
in spite of the fact that the body weight ratio between the
two species was about 1,000.
The targeting experiments showed that the binding of both
antibodies to the specific target did increase with increasing
number of tumour cells (Figures 5 and 6, Table IV). Ana-
logous to an in vitro assay, the degree of increase in the
antibody uptake with increasing amount of tumour cells
reflects partly the antibody avidity for the cells, and partly
the number of specific binding sites on the cell surfaces
relative to the amount of antibody available.
When comparing the results in mice and pigs, we found
that the DC:blood ratios recorded in the pigs (Figures 5 and
6) were of the same order of magnitude as the ratios
previously achieved in mice (Figure 3), whereas the DC
uptake relative to injected dose was definitely lower in the
pigs (Table IV) than in the mice (Table II). The fraction of
injected TP-1-F(ab')2 bound in the pig DC with 2 x i05 cells
was 1/300 times the mouse DC uptake (2 x 105 cells). With
H7-Fab the DC with half the cell number (i.e. 105 cells) did
bind as much as 1/60 the uptake in the mice. Thus, the DC
uptake values in pigs were definitely higher than expected
from the mouse results.
Several pig tissue specimens were explored for their radio-
activity uptake, without being presented in Figure 5 and
Figure 6. There was an overall low radioactivity level in all
these tissues. Different bone and cartilage specimens were
carefully controlled for uptake of the anti-sarcoma antibody,
and the level was low also in these tissues.
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Figure 5 Biodistribution and immunotargeting of human
tumour cells in a pig 24 h after i.v. injection of '25I-labelled
H7-Fab. Each bar represents the median and range for 3 DC, or
single values for tissue specimens.
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Figure 4 Blood concentration of '25I-labelled H7-Fab (O---0)
and TP-l-F(ab')2 (@ *) injected i.v. on pigs. Single observa-
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Figure 6 Biodistribution and human tumour cell targeting of
'25l-labelled TP-l-F(ab')2 in a pig 72h after i.v. injection. See
legend to Figure 5.
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Table IV Percentage of administered dose of '25I-MoAb specifically
bound to different amounts of target cells in intraperitoneal DC in
pigs
No. cells ( x 10-') % Bound ( x 103)
H7-Fab 50 5.9 (4.5-7.1)
vs Hep-2 cells 10 3.3 (3.2-4.2)
24h 5 3.0 (3.0-4.2)
1 1.3 (1.2-1.6)
TP-1-F(ab')2 100 10.7 (8.6-10.9)
vs OHS cells 20 6.1 (5.0- 6.6)
72 h 7 3.0 (2.7- 3.2)
2 1.1 (1.0- 1.6)
1 0.4 (0.4- 0.8)
One pigwasinjected i.v. with 1,200 pmol theH7-Fabantibody, and a
second pig was injected with 1,200 pmol TP-l-F(ab')2. The results have
been corrected for the non-specific binding to DC with control cells.
Discussion
The main purpose of the preclinical in vivo evaluation of
tumour specific MoAb is to measure the specific binding to
the tumour cells, and to compare this with the antibody level
in blood and the tissues. We here demonstrate that a
diffusion chamber (DC) model can be utilised for this pur-
pose in immunocompetent mice, and in xenogeneic species as
well, domestic pigs being chosen in the present work.
The fact that immunocompetent animals of any species can
be utilised is an important advantage of the model. As
expected, we did find that the fraction of injected dose bound
to the DC was much lower in large animals (pigs) than in
small animals (mice). If we assume that the antibody distri-
bution volume is the same fraction of the body weight in
both species, then the distribution volume in pigs will be
1,000 times the distribution volume in mice. Then, according
to the law of passive diffusion, the fraction of the injected
dose diffusing into the DC in a pig should theoretically be
about 1/1,000 times the value in a mouse, if the concentra-
tion of antibodies accessible to the DC was the same in the
two species. However, the antibody uptake in the DC in pigs
was higher than 1/1,000 the mouse results with the same DC,
in spite of the fact that a five times lower weight-related dose
had been administered to the pigs. We believe that the
answer to this high DC uptake in the pigs may be that the
blood clearance of the injected antibodies is slower in these
animals than in the mice. This species difference in clearance
rate was larger with the H7-Fab than with the TP-1-F(ab')2
antibody, and this may explain why the difference between
measured and expected DC uptake in pigs was largest with
the Fab antibody.
A very low percentage of the dose administered was
expected to be bound to the relatively small amount of target
cells in the DC. However, the fraction of the i.v. injected
MoAb bound to 160 l target cell suspension, in DC placed
intraperitoneally in mice, was comparable to the amount of
antibody bound per gram xenograft tissue in nude mice.
Assuming an average cell diameter of 20 tLm, 1 g of xenograft
tissue contains about 1,000 times more cells than the DC.
Thus, the antibody accessibility to the specific tumour cell
antigen was definitely better in the DC cell suspension than
in the nude mouse xenograft tissue. The explanation prob-
ably is that the antibody transport into solid tumours is
hampered by anatomical and physiological barriers (Cobb,
1989; Jain, 1990). This may be one of the main reasons for
the problems experienced in clinical immunotargeting. How-
ever, we believe that a second main reason is that in the
clinical situation, like in the pig experiments here presented,
the antibody distribution volume is very large relative to the
tumour volume. The low fraction of injected dose in the DC
in the pigs corresponds to the low fractions accumulating in
the tumour tissue in most clinical trials, usually between
0.001 and 0.01% g-' (Sands, 1990).
With the DC model it was also possible to compare in vivo
and in vitro MoAb binding to the same target. In vitro, the
F(ab')2 uptake was somewhat higher than with the Fab
fragment of the other MoAb, in spite of the fact that the
avidity of the Fab was definitely higher. This means that the
lower avidity of the F(ab')2 was compensated by the higher
immunoreactive fraction and the higher number of binding
sites on the target cells. In vivo, this difference between the
specific uptake of the two antibodies was largely increased.
The in vivo concentration of immunoreactive MoAb available
for'reaction with the tumour cells is continuously reduced
because the antibodies are catabolised, non-specifically bound
in normal tissues, or, when small antibody fragments are
used, excreted by the kidneys. This reduction in antibody
concentration is presumably the main reason why a lower
tumour uptake was recorded in vivo, especially in the case of
the Fab antibody. In the experiments here presented the
uptake with the Fab antibody was 40-50 times lower in mice
than in vitro, whereas the in vivo tumour cell uptake with the
F(ab')2 antibody was only 6-7 times lower than in vitro. It is
thus difficult to achieve a high % injected dose in the target
with a rapidly cleared antibody. On the other hand, a rapid
blood clearance is preferred in tumour targeting studies
because it reduces the background radiation.
Graft rejection is no problem in this model system. The
immunocompetent cells of the host can not traverse the DC
membrane wall. Theorectically though, the host humoral
immune apparatus might be stimulated by immunogenic cell
components that are shed from the tumour cells, and are
small enough to leave the DC through the micropores. How-
ever, the period between i.p. implantation and harvest of the
DC did not exceed 4 days, which is too short a time for an
efficient primary humoral host versus graft response to
develop. The cell viability and cell number in the DC in mice
were followed in preliminary experiments not presented.
Reliable registrations ofcell growth and viability is first ofall
needed in immunotherapy studies. The total number of cells
seemed to be constant during the observation period (3
days), and the fraction of dead cells (trypan blue dye ex-
clusion test) increased from about 10% after I day in the DC
to 20-40% after 3 days. However, the fraction of dead cells
did not seem to influence the antibody uptake, at least not
within the time intervals and the number of cells and anti-
body doses here used. Thus, when implanting DC with more
than 50% trypan blue positive cells, we did not find uptake
values significantly different from DC filled with cell suspen-
sions with only 5% dead cells. We think that the reason for
this is that the dead cells do not disintegrate to a con-
siderable extent during the short observation period, but
remain within the DC, and retain the ability to bind the
antibodies. This may not be valid for other cell antigens.
Non-specific antibody binding in normal tissues is gener-
ally observed in immunotargeting. When the MoAb is given
to species other than mice, a more reliable preclinical evalua-
tion of the interaction with normal tissues is achieved. The
probability for an immunological cross-reaction between
murine MoAb and mouse tissues is low. However, when
species other than mice are used, the MoAb are xenogeneic
to the host animal, like in patients. The xenogeneic antibody
transfer of murine MoAb to pigs in the present paper dem-
onstrated a specific tumour cell targeting also in this species.
This may predict that the MoAb preparations here utilised
also have a good targeting potential in patients. In fact,
promising results have now been achieved with TP-1 in
several bone sarcoma patients (Bruland et al., manuscript in
preparation), and with H7 on ovarial cancer patients (Stig-
brand et al., manuscript in preparation).
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